{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:00:00Z","timestamp":1791500400920,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.clinthera.2008.11.014","type":"journal-article","created":{"date-parts":[[2008,12,25]],"date-time":"2008-12-25T05:20:57Z","timestamp":1230182457000},"page":"1956-1975","source":"Crossref","is-referenced-by-count":159,"title":["Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia"],"prefix":"10.1016","volume":"30","author":[{"given":"David L.","family":"DeRemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.11.014_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2008.11.014_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: Biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib3","first-page":"49","article-title":"Staging and prognosis in chronic myelogenous leukemia","volume":"25","author":"Sokal","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2141.1997.3453159.x","article-title":"Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse","volume":"99","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: A concise update","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib6","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics o f Tumours of Haematopoietic Lymphoid Tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.clinthera.2008.11.014_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2008.11.014_bib8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib10","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable longterm follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferonalpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib13","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast cri sis: Results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib15","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Phila delphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: The new wave of BCR-ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2008.11.014_bib17","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2008.11.014_bib19","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CMLand Philadelphia chromosome positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib20","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib21","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AM N107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib23","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib24","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic res ponses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib25","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic re sponses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib26_1","unstructured":"US National Institutes of Health, National Cancer Institute. FDA approval for dasatinib [NCI Web site]."},{"key":"10.1016\/j.clinthera.2008.11.014_bib27_1","unstructured":"US National Institutes of Health, National Cancer Institute. FDA approval for nilotinib [NCI Web site]."},{"key":"10.1016\/j.clinthera.2008.11.014_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1365-2141.1999.01736.x","article-title":"Chronic myelogenous leukaemia with p185(BCR\/ABL) expression: Characteristics and clinical significance","volume":"107","author":"Ravandi","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0145-2126(01)00197-7","article-title":"Bcr-Abl variants: Biological and clinical aspects","volume":"26","author":"Advani","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2008.11.014_bib30","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib31","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.11664","article-title":"The biology and therapy of adult acute lymphoblastic leukemia","volume":"98","author":"Faderl","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib32","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia-advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"NAt Rev Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib34","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clinthera.2008.11.014_bib36","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinibresistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2008.11.014_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1476-4598-6-67","article-title":"Nilotinib treatment in mouse models of P190 Bcr\/Abl lymphoblastic leukemia","volume":"6","author":"Kaur","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib38","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/cncr.21299","article-title":"AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells","volume":"104","author":"Verstovsek","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib39","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS 354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2008.11.014_bib40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","article-title":"Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AM N107)","volume":"108","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib41","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","article-title":"Low-level expression of proapoptotic Bcl-2 interacting mediator in leukemic cells in patients with chronic myeloid leukemia: Role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds","volume":"65","author":"Aichberger","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2008.11.014_bib42","series-title":"Presented at: 98th AACR Annual Meeting; April 14-18; Los Angeles, Calif","article-title":"Extended kinase profiling of the Bcr-Abl inhibitor nilotinib","author":"Manley","year":"2007"},{"key":"10.1016\/j.clinthera.2008.11.014_bib43_1","unstructured":"Tasigna (nilotinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2007."},{"issue":"Suppl 18","key":"10.1016\/j.clinthera.2008.11.014_bib44","article-title":"Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed\/refractory Ph+ acute lymphocytic leukemia (Ph+ ALL)","volume":"24","author":"Tanaka","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.4887.4887","article-title":"Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects","volume":"106","author":"Kagan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib46","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: Im plications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2364.2364","article-title":"Characterisation of nilotinib transport in chronic myeloid leu kaemia cells","volume":"110","author":"Davies","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2379.2379","article-title":"Pharmacokinetics in nilotinib in subjects with normal or impaired hepatic function","volume":"110","author":"Holland","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib50","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib51","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic-phase chronic myelogenousleukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib52_1","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Chronic myelogenous leukemia."},{"key":"10.1016\/j.clinthera.2008.11.014_bib53","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.11.014_bib54","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the manage ment of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib55","article-title":"Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CMLCP): Updated phase II results","volume":"26","author":"Kantarjian","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib56","article-title":"Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or -intolerance: Update of a phase II study","volume":"26","author":"le Coutre","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib57","series-title":"Presented at: 12th Congress of the European Hematology Association (EHA); June 7-10; Vienna, Austria","article-title":"Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory acute lymphoblastic leukemia (ALL)","author":"Ottman","year":"2007"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib58","article-title":"Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML CP)","volume":"26","author":"Cortes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib59","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2149.2149","article-title":"Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: An update from the RIGHT Trial Study Group","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib60","article-title":"Nilotinib in chronic myelogenous leukemia in blast crisis (CMLBC) patients with imatinib-resistance or -intolerance: Update phase II results","volume":"26","author":"Giles","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib61","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1200\/jco.2008.26.15_suppl.10553","article-title":"A Phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST). Study update","volume":"26","author":"Blay","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib62_1","unstructured":"A randomized, open-label, multicenter study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinib."},{"key":"10.1016\/j.clinthera.2008.11.014_bib63","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: No evidence for increased transplantrelated toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/sj.bmt.1705683","article-title":"Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib","volume":"40","author":"Menzel","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2008.11.014_bib65","author":"Shimoni","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2008.11.014_bib66","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705087","article-title":"Imatinib therapy prior to myeloablative allogeneic stem cell transplantation","volume":"36","author":"Zaucha","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib67","article-title":"A phase II study of nilotinib administered to patients with imatinib re sistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib","volume":"25","author":"Giles","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib68","article-title":"Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib69","article-title":"Expanding nilotinib access in clinical trials (ENACT) study in adult patients (pts) with imatinib resistant or -intolerant chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or chronic phase (CP): Preliminary safety analysis","volume":"110","author":"Nicolini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib70_1","unstructured":"A phase III randomized, open- label multi-center study of nilotinib versus imatinib in adult patients with ph+ chronic myelogenous leukemia in chronic phase (CML CP) who have a suboptimal cytogenetic response (CyR) on imatinib [clinicaltrials.gov Web site]."},{"key":"10.1016\/j.clinthera.2008.11.014_bib71_1","unstructured":"A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CMLCP) [clinicaltrials.gov Web site]."},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib72","article-title":"Incidence of grade 3\/4 adverse events in imatinib resistant\/intolerant chronic phase CML (CPCML): A comparison of nilotinib and dasatinib","volume":"25","author":"Carpiuc","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib73","article-title":"Grade 3\/4 adverse events (AEs) of second generation tyrosine kinase inhibitors (TKIs) for imatinib resistant\/Intolerant patients in accelerated phase CML (AP-CML)","volume":"25","author":"Snedecor","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib74","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treat ment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib75","article-title":"Pleural effusion in patient (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure","volume":"108","author":"Quintas-Cardama","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib76","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.11.014_bib77","series-title":"Presented at: 13th Congress of the European Hematology Association (EHA); June 12-15; Copenhagen, Denmark","article-title":"The occurrence of pleural\/pericardial effusions in Ph+ CML patients failing prior tyrosine kinase inhibitors (TKI) before starting nilotinib- Analysis of data from compassionate use program","author":"Le Coutre","year":"2008"},{"key":"10.1016\/j.clinthera.2008.11.014_bib78_1","unstructured":"Patient Assistance Foundation enrollment [Novartis Web site.]."},{"key":"10.1016\/j.clinthera.2008.11.014_bib79","doi-asserted-by":"crossref","first-page":"570","DOI":"10.18553\/jmcp.2006.12.7.570","article-title":"Pharmacy benefit spending on oral chemotherapy drugs","volume":"12","author":"Curtiss","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2008.11.014_bib80","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.clinthera.2004.11.007","article-title":"Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase","volume":"26","author":"Warren","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2008.11.014_bib81","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.20694","article-title":"Cost-effectiveness of imatinib versus interferon-alpha plus low dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Reed","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2008.11.014_bib82","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1592\/phco.25.3.325.61593","article-title":"Costefficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: A decision-analytic approach","volume":"25","author":"Skrepnek","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2008.11.014_bib83","series-title":"2007 Drug Topics Red Book","year":"2007"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib84","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/blood.V110.11.5177.5177","article-title":"Cost of myelosuppression with the second generation tyrosine kinase inhibitors (TKIs) in imatinib resistant\/Intolerant chronic myelogenous leukemia (CML): An economic analysis usingglobal literature","volume":"110","author":"Stephens","year":"2007","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib85","article-title":"The cost of managing pleural effusion associated with dasatinib in CML patients post imatinib failure","volume":"110","author":"Stephens","year":"2007","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.11.014_bib86","article-title":"IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"110","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib87","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib88","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T3151 mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib89","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.11.014_bib90","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia pa tients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2008.11.014_bib91","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000108639","article-title":"Nilotinib can override dasatinib resistance in chronic myeloid leuke mia patients with secondary resis tance to imatinib first-line therapy","volume":"118","author":"Breccia","year":"2007","journal-title":"Acta Haematol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808004086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808004086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T17:12:48Z","timestamp":1632849168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808004086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0149291808004086"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.11.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}